Form 424B5 NeuBase Therapeutics, streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully redose a gene editor without an immune r.
PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
By Josh Beckerman NeuBase Therapeutics is raising $5 million in a registered direct offering and private placement. The genetic medicines company is selling.